NASDAQ:CTIC - CTI BioPharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.95 +0.03 (+3.26 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$0.92
Today's Range$0.92 - $0.95
52-Week Range$0.60 - $5.36
Volume236,700 shs
Average Volume380,231 shs
Market Capitalization$55.09 million
P/E Ratio-0.76
Dividend YieldN/A
Beta1.75
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. The company's product candidate in pipeline includes tosedostat, a novel oral, once-daily aminopeptidase inhibitor for patients with acute myeloid leukemia. It has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; Teva Pharmaceutical Industries Ltd; University of Vermont; S*BIO Pte Ltd; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Receive CTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTIC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTIC
Previous SymbolNASDAQ:CTICD
CUSIPN/A
Phone206-282-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$25.15 million
Book Value$0.35 per share

Profitability

Net Income$-40,670,000.00
Net Margins-361.97%

Miscellaneous

Employees57
Market Cap$55.09 million
OptionableOptionable

CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?

Shares of CTI BioPharma reverse split before market open on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp (NASDAQ:CTIC) announced its quarterly earnings data on Thursday, August, 2nd. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.03. The biopharmaceutical company had revenue of $0.61 million for the quarter, compared to analyst estimates of $0.30 million. CTI BioPharma had a negative return on equity of 85.84% and a negative net margin of 361.97%. View CTI BioPharma's Earnings History.

When is CTI BioPharma's next earnings date?

CTI BioPharma is scheduled to release their next quarterly earnings announcement on Wednesday, March 6th 2019. View Earnings Estimates for CTI BioPharma.

What price target have analysts set for CTIC?

4 equities research analysts have issued 1 year price objectives for CTI BioPharma's stock. Their forecasts range from $4.00 to $10.00. On average, they expect CTI BioPharma's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 584.2% from the stock's current price. View Analyst Price Targets for CTI BioPharma.

What is the consensus analysts' recommendation for CTI BioPharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CTI BioPharma.

Has CTI BioPharma been receiving favorable news coverage?

Media headlines about CTIC stock have been trending somewhat positive on Friday, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CTI BioPharma earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.

Who are some of CTI BioPharma's key competitors?

Who are CTI BioPharma's key executives?

CTI BioPharma's management team includes the folowing people:
  • Dr. Adam R. Craig, Pres, CEO & Director (Age 53)
  • Dr. Jack W. Singer, Co-Founder & Consultant (Age 76)
  • Mr. David H. Kirske, Exec. VP & CFO (Age 65)
  • Mr. Bruce J. Seeley, COO, Exec. VP & Sec. (Age 55)
  • Mr. Ed Bell, Sr. Director of Investor Relations

Who are CTI BioPharma's major shareholders?

CTI BioPharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (9.88%), Opaleye Management Inc. (2.41%), Fosun International Ltd (0.52%), Two Sigma Advisers LP (0.20%), Rhumbline Advisers (0.11%) and SG Americas Securities LLC (0.08%). Company insiders that own CTI BioPharma stock include Bvf Partners L P/Il, Richard L Love and Value Fund L P Biotechnology. View Institutional Ownership Trends for CTI BioPharma.

Which major investors are selling CTI BioPharma stock?

CTIC stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc.. View Insider Buying and Selling for CTI BioPharma.

Which major investors are buying CTI BioPharma stock?

CTIC stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Fosun International Ltd, SG Americas Securities LLC, Rhumbline Advisers and Two Sigma Advisers LP. Company insiders that have bought CTI BioPharma stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for CTI BioPharma.

How do I buy shares of CTI BioPharma?

Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $0.95.

How big of a company is CTI BioPharma?

CTI BioPharma has a market capitalization of $55.09 million and generates $25.15 million in revenue each year. The biopharmaceutical company earns $-40,670,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. CTI BioPharma employs 57 workers across the globe.

What is CTI BioPharma's official website?

The official website for CTI BioPharma is http://www.ctibiopharma.com.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]


MarketBeat Community Rating for CTI BioPharma (NASDAQ CTIC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  201 (Vote Outperform)
Underperform Votes:  229 (Vote Underperform)
Total Votes:  430
MarketBeat's community ratings are surveys of what our community members think about CTI BioPharma and other stocks. Vote "Outperform" if you believe CTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel